Should I Take Antidepressants Quiz

People uncertain about whether to raise antidepressants with a prescriber can use the Should I Take Antidepressants Quiz to clarify what may need attention before an appointment. This antidepressant quiz is intended for someone facing a difficult treatment decision, revisiting an unhelpful treatment history, or wondering how prepared they are to seek advice. Its result can help distinguish urgent concerns from questions to bring to the conversation.

What This Assessment Explores

The questionnaire examines symptoms' daily-life effects, safety concerns, and treatment preferences. Items cover low mood, loss of interest, anxiety, hopelessness, emotional numbness, concentration, emotional control, impulsivity, substance-related danger, unusual perceptions, self-harm thoughts, and willingness to involve a clinician. It frames antidepressant treatment options without deciding which is appropriate.

Displayed scales are:

• Safety & Urgency Flags (0-10) captures warning signs that may call for prompt or urgent professional help, including emergency care when safety is at risk; Low concern 0-3, Moderate concern 4-6, and High concern 7-10.
• Symptom Severity & Impact (0-30) measures symptom intensity and daily disruption; Low impact 0-10, Moderate impact 11-20, and High impact 21-30.
• Treatment Readiness (0-20) reflects openness and practical readiness to have a medication-focused conversation and consider a monitored trial when clinically appropriate; Low readiness 0-6, Moderate readiness 7-13, and High readiness 14-20.

Methodology and Scientific Basis

Response choices vary by topic: agreement, frequency, intensity, access, or willingness. The questionnaire uses varied response formats across recent symptoms, safety situations, and treatment preferences, and does not specify how individual responses contribute to each displayed scale, so the ranges cannot be used to infer a point-by-point scoring rule.

Closest is Depression Medication Choice (LeBlanc et al., 2015), which centers shared decision-making around antidepressant benefits, risks, alternatives, and preferences. The PHQ-9 (Kroenke et al., 2001) offers a conceptual comparison for symptom severity, while the Columbia-Suicide Severity Rating Scale (Posner et al., 2011) is relevant to the safety themes. The questionnaire is conceptually consistent with these works, not an adaptation or validation of them.

Because the online tool is not presented as a normed diagnostic instrument, it cannot choose a medication or establish clinical eligibility; a medication readiness assessment still requires clinical history, diagnosis, risks, preferences, and professional evaluation. Current circumstances, recall, self-awareness, and willingness to disclose can affect self-report, while immediate danger calls for prompt professional or emergency help rather than waiting for a score.